ArticleJAMA cardiology2017

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.

Gregg C Fonarow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.